DOD Glioblastoma, Hypothesis Development Award
ID: 356428Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

    Point(s) of Contact
    Files
    Title
    Posted
    The Fiscal Year 2024 Department of Defense Glioblastoma Research Program (GBMRP) outlines two primary award mechanisms: the Hypothesis Development Award and the Resource Development Award. Both awards target independent investigators at all career levels, emphasizing the encouragement of early-career researchers. The Hypothesis Development Award supports innovative, exploratory research addressing significant issues in glioblastoma, particularly in drug delivery and biomarkers. A Letter of Intent is mandatory before applying, and the funding caps are set at $200,000 for single principal investigators and $300,000 for partnering teams, with a performance period of up to two years. In contrast, the Resource Development Award focuses on enhancing preclinical model systems necessary for glioblastoma research. Applicants must provide preliminary data, with funding available up to $500,000 for direct costs and a maximum performance period of three years. Similar to the previous award, a Letter of Intent is required. Both awards exclude clinical trials but permit related clinical and animal research. The submission deadlines for both awards are November 6, 2024 (Letter of Intent) and November 20, 2024 (full application). This document serves as a vital resource for researchers seeking funding opportunities within the federal framework, reinforcing the government’s commitment to advancing glioblastoma research through well-structured grant mechanisms.
    The Department of Defense (DOD) is soliciting applications for the fiscal year 2024 Glioblastoma Hypothesis Development Award (HDA) under its Congressionally Directed Medical Research Programs (CDMRP). This program aims to fund innovative research that improves glioblastoma patient survival and reduces negative impacts on Service Members and the broader American public. Planning a two-step application process, the deadlines for submissions are set for November 6, 2024 (pre-application) and November 20, 2024 (full application). The total funding available is approximately $10 million, with awards supporting projects that address relevant experimental focus areas such as drug delivery and biomarker identification. Eligibility spans a wide range of organizations, including academic institutions and private entities. Applicants are encouraged to present groundbreaking concepts without the need for preliminary data, emphasizing significant potential impact. Specifics such as funding limits, submission protocols via eBRAP and Grants.gov, and review criteria guide the application process. The awards will facilitate exploration into glioblastoma, particularly the IDH-wild type forms, through rigorous scientific inquiry that directly benefits the affected communities and enhances medical research.
    Similar Opportunities
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant, Idea Discovery Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Reconstructive Transplant Idea Discovery Award, a federal grant aimed at supporting innovative and high-risk research in reconstructive transplant and immunotherapy. This grant seeks to generate robust data that can lead to new scientific investigations, particularly focusing on enhancing immunosuppression techniques and advancing tissue preservation strategies relevant to military personnel and veterans. With an estimated total program funding of $2.5 million, the award will provide up to $500,000 for each selected project over a two-year period, contingent upon the availability of federal funds and the merit of applications. Interested applicants must submit a pre-application by August 7, 2024, followed by a full application due by October 23, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant, Advanced Technology Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Reconstructive Transplant Advanced Technology Development Award, aimed at supporting innovative research in reconstructive transplantation for injured Service Members and Veterans. This grant opportunity encourages the development of products such as drugs, biologic agents, and clinical practice guidelines, with a focus on enhancing techniques and access to reconstructive transplantation. The program has an estimated total funding of $3.5 million, with awards of up to $1.5 million available for applications involving multiple principal investigators. Interested applicants must submit a pre-application by August 7, 2024, followed by a full application due by October 23, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    Toxic Exposures Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Toxic Exposures Clinical Trial Award under the Toxic Exposures Research Program (TERP). This grant aims to support the rapid implementation of clinical trials that address health outcomes related to military-related toxic exposures, with a focus on prevention, treatment, and management of associated symptoms and diseases. The program emphasizes the importance of collaboration between the Department of Defense and the Department of Veterans Affairs, seeking proposals that align with specific program goals and topic areas, such as neurotoxin exposure and Gulf War Illness. The total estimated funding for this initiative is $10.4 million, with applications due by November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Reconstructive Transplant Research, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is inviting applications for the FY24 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, aimed at advancing reconstructive transplant research and improving healthcare for military service members and veterans. This grant opportunity seeks proposals that focus on vascularized composite allotransplantation (VCA) and immunotherapy, emphasizing the optimization of immunosuppressive techniques, identification of noninvasive biomarkers for graft rejection monitoring, and development of tissue preservation strategies. With an estimated total program funding of $4 million, individual principal investigator applications can receive up to $1 million, while multiple principal investigator collaborations may secure up to $1.5 million, contingent upon successful peer review. The pre-application deadline is August 7, 2024, and the full application deadline is October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    DoD Reconstructive Transplant, Qualitative Research Validation and Implementation Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Reconstructive Transplant, Qualitative Research Validation and Implementation Award, aimed at advancing qualitative research in reconstructive transplantation. This grant seeks to validate and implement resources developed from previous studies related to vascularized composite allotransplantation (VCA), focusing on improving outcomes for service members, veterans, and the broader community. The total funding available for this opportunity is $500,000, with a maximum budget for individual projects capped at the same amount, and applications are due by October 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    Toxic Exposures Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TRA) to support research on adverse health outcomes related to military toxic exposures. This grant aims to facilitate translational research that bridges basic science and clinical applications, focusing on developing diagnostics, treatment strategies, and understanding exposure mechanisms to improve health care for service members and their families. With an estimated total program funding of $12.8 million and the expectation of awarding six grants, applicants must submit a pre-application by August 13, 2024, followed by a full application due by November 7, 2024. For further inquiries, interested parties can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.